Counselors in Eastman, GA Accepting Medicare

5 Counselors found. Showing 1 - 5

Ben Thompson, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1445 Cochran Hwy, Eastman, GA 31023 Phone: 478-231-5670

David Wesley Evans, L.P.C. Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 133 Pal Rd, Eastman, GA 31023 Phone: 478-374-7968

Mr. Joe Franklin Chapman Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 81 Constitution Street, None, Eastman, GA 31023 Phone: 478-919-4903

Chelse Louise Stuckey Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 5205 Park St, Eastman, GA 31023 Phone: 478-231-9079

Mr. Fred Jackson Lee, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1155 Brookwood Dr, Eastman, GA 31023 Phone: 478-278-7585

News Archive

HDSA honors outstanding contributors against Huntington's Disease

The Huntington's Disease Society of America (HDSA), will recognize the outstanding contributions to improving the quality of life of people with Huntington's Disease (HD) by several individuals and two organizations at the 13th annual Guthrie Awards Dinner this Thursday.

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study's primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

Two-gene DNA urine test for prostate cancer

In the current debate sparked by the recent USPSTF recommendation on PSA screening, it is clear that better biomarkers than PSA are urgently needed. One new biotechnology that may go a long way in detecting only prostate cancer and reducing unnecessary prostate cancer biopsies and possible subsequent overtreatment, is the development of a new urine test for prostate cancer.

Remote controlled microchip successfully delivers drug in early clinical trial

Researchers have developed a new microchip implant device that can deliver bone-building drugs to seven osteoporosis patients. The microchips worked inside patients as drug-delivering pacemakers, following a prescription plan sent by radio signal.

CSL Plasma chooses OrSense's NBM200 Hb testing device for screening Hb levels in plasma donors

OrSense Ltd., developer of solutions for non-invasive measurements of hemoglobin, today announced that CSL Plasma, Germany, has completed the transition to OrSense's NBM200 Hb testing device for screening of Hb levels in plasma donors.

Read more Medical News

› Verified 4 days ago